ARVO Meeting Coverage Day 2: Pipeline Therapies in GA
Could RPE cell replacement therapy be the future of GA treatments? Retina Today’s Chief Medical Editor Allen C. Ho, MD, joined us to discuss observations from a phase 1/2a study evaluating the safety and efficacy of OpRegen (Lineage Cell Therapeutics), a suspension of allogenic RPE cells implanted in the subretinal space. How well was this therapy tolerated, and were there any signs of vision improvement? Elsewhere in the GA pipeline, researchers are exploring whether the gene therapy GT005 (Gyroscope Therapeutics) might be a safe and effective one-time treatment for GA via upregulation of complement factor I. How does complement factor I affect the course of GA, and what are the latest data from a phase 1/2 study? Check out this episode to hear on conversation on that topic with Jared Nielsen, MD, MBA. This podcast is editorially independent, supported with advertising.